← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
26	26 Invesco Biotechnology & Genome ETF PBE $429M	87	+5	+6%	$166M
27	27 Arbutus Biopharma ABUS $850M	77	+28	+57%	$616M
28	BLCM 28 DELISTED Bellicum Pharmaceuticals, Inc. BLCM	71	+16	+29%	$340M
29	29 Lineage Cell Therapeutics LCTX $232M	69	+10	+17%	$152M
30	30 DELISTED NeuBase Therapeutics, Inc. Common Stock NBSE	64	+11	+21%	$18.5M
31	NSTG 31 DELISTED NanoString Technologies, Inc. NSTG	61	+1	+2%	$139M
32	AGTC 32 DELISTED Applied Genetic Technologies Corporation AGTC	59	+11	+23%	$178M
33	ATHX 33 DELISTED Athersys, Inc. Common Stock ATHX	53	+6	+13%	$26.2M
34	34 Atara Biotherapeutics ATRA $96.9M	53	+14	+36%	$462M
35	NVTA 35 DELISTED Invitae Corporation NVTA	52	+52	–	$302M
36	36 DELISTED Carisma Therapeutics CARM	51	+10	+24%	$119M
37	37 Fortress Biotech FBIO $63.7M	49	+13	+36%	$33.7M
38	38 Veracyte VCYT $3.57B	48	0	0%	$69.3M
39	39 Cellectis CLLS $111M	44	+44	–	$213M
40	40 uniQure QURE $1.56B	41	+13	+46%	$120M
41	41 ProQR Therapeutics PRQR $205M	38	+3	+9%	$241M
42	42 Opus Genetics IRD $337M	35	-3	-8%	$5.94M
43	43 Vericel Corp VCEL $2.1B	35	0	0%	$40.1M
44	44 Pluri PLUR $11.9M	32	+3	+10%	$4.27M
45	45 CareDx CDNA $3.45B	26	+7	+37%	$29.7M
46	46 Imunon IMNN $5.95M	26	-7	-21%	$7.42M
47	47 Fate Therapeutics FATE $231M	25	+2	+9%	$51.9M
48	48 Neurogene NGNE $479M	25	+3	+14%	$34.1M
49	49 DELISTED BRAINSTORM CELL THERAPUTC BCLI	21	+10	+91%	$10.7M
50	50 DELISTED BioLife Solutions BLFS	15	0	0%	$681K